Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.~Inclusion Criteria:~* CP-CML who prove resistant or intolerant to imatinib (Cohort 1)~* Ph+ ALL, AP-CML, or BP-CML who are resistant or intolerant to or who relapse after imatinib therapy (Cohort 2)~* Newly diagnosed, treatment naive CP-CML (Cohort 3)~* Lansky or Karnofsky scale \>50~* Life expectancy ≥12 weeks~* Adequate hepatic and renal function~* Written informed consent~* Target Population for the PK substudy must obtain written informed consent from subject, or from parents or legal guardians for minor subjects, according to local law and regulation~* Target Population for the PK substudy subjects must have CP-CML and be taking daily dasatinib (tablets or PFOS) either as part of Cohort 1 or Cohort 3 of this protocol. Patients receiving commercial dasatinib tablets outside of this protocol may be invited to participate in this PK substudy~* Target Population for the PK substudy subjects with CP-CML who are tolerating dasatinib tablet dose of at least 60 mg/m2 or dasatinib PFOS dose of at least 72 mg/m2~* Target Population for the PK substudy prior exposure to imatinib or other TKI therapy is permissible~* Target Population for the PK substudy subjects must meet relevant inclusion criteria~Exclusion Criteria:~* Eligibility for potentially-curative therapy including hematopoietic stem-cell transplantation~* Symptomatic CNS involvement (other than signs and symptoms caused by leptomeningeal disease)~* Isolated extramedullary disease~* Prior therapy with Dasatinib~* Target Population for the PK substudy subjects participating in the PK substudy must comply with the relevant exclusion criteria~* Target Population for the PK substudy subjects are not allowed to use proton pump inhibitors, H2 antagonists, CYP3A4 inhibitors and inducers when entering the PK substudy~Other inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 1 Day
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Imatinib-resistant/intolerant CP-CML (Type: EXPERIMENTAL): Dasatinib 60 mg/m² tablet every day (QD) \[with a maximum dose of 100 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² powder for oral suspension (PFOS) QD \[with a maximum dose of 120 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit
- Cohort 2: Ph+ALL or AP- or BP-CML (Type: EXPERIMENTAL): Dasatinib 80 mg/m² tablet QD \[with a maximum dose of 140 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 96 mg/m² PFOS QD \[with a maximum dose of 170 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit
- Cohort 3: Newly diagnosed, treatment naïve CP-CML (Type: EXPERIMENTAL): Dasatinib 60 mg/m² tablet QD \[with a maximum dose of 100 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit~OR~Dasatinib 72 mg/m² PFOS QD \[with a maximum dose of 120 mg QD for subjects with high BSA\] for minimum of 24 months, may continue as long as deriving clinical benefit

Based on this trial design, predict the completion outcome and termination type (if applicable).